Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

NCT03639948 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Pembrolizumab
DRUG: Pegfilgrastim

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]